New HAE drug shows promise in early trial
Disease control
Completed
This study tested a new drug, navenibart, in 29 people with hereditary angioedema (HAE), a condition that causes sudden, painful swelling. Participants received one or two doses of the drug to see if it is safe and helps reduce swelling attacks. The goal is to find a better way t…
Phase: PHASE1, PHASE2 • Sponsor: Astria Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 10:52 UTC